Competition is heating up, but questions remain about insurance coverage, drug pricing, copycat drugs and the role of pills in the space.

For the first time in years, the obesity rate is falling in the US, with the rise of weight loss injections like Ozempic and ...

Novo Nordisk attempts to acquire weight-loss drug company Metsera during government shutdown, potentially avoiding FTC ...

Semaglutide appears to safeguard the heart even when patients lose little weight. In a massive international trial, heart attack and stroke risk dropped by 20% regardless of BMI. The benefit seems ...

Founded in 2022 by Population Health Partners and ARCH Venture Partners, the biotech venture giant led by Bob Nelsen, Metsera ...

Reuters further highlighted that Novo Nordisk A/S (NYSE:NVO), which initially celebrated the success of its obesity drug, has ...

Danish pharmaceutical giant Novo Nordisk, maker of weight-loss drugs Ozempic and Wegovy, announced Thursday an unsolicited ...

Novo Nordisk raises its bid for obesity drugmaker Metsera to outmanoeuvre Pfizer, reshaping the fast-growing weight-loss ...

Shares of Indian generic drugmaker Dr Reddy's Laboratories declined more than 5% on Thursday, after the firm received a non-compliance notice for its semaglutide injection in Canada, which analysts ...

A few things happen when you get a corticosteroid injection at the dermatologist’s office. “We inject it into active inflamed ...

Somehow, it’s becoming even harder to get a GLP-1.